Viking Therapeutics

California, United States Founded: 2012 • Age: 14 yrs Listed
Small molecule therapies for endocrine and metabolic disorders are developed.

About Viking Therapeutics

Viking Therapeutics is a publicly listed company based in United States founded in 2012. Small molecule therapies for endocrine and metabolic disorders are developed. Viking Therapeutics has raised $2.5 million across 1 funding round from investors including Ligand Pharmaceuticals. The company has 36 employees. Its chief executive, as recorded, is Brian Lian. Its website vikingtherapeutics.com draws about 31 thousand monthly visits. Viking Therapeutics offers products and services including VK2735, VK2809, VK0214, and VK5211. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Endocrine disorders. Its legal entity is VIKING THERAPEUTICS, INC. Its competitors include Neurocrine, Crinetics and Carmot; 3 of its 3 listed competitors have raised funding.

Company details

Viking Therapeutics was founded in 2012 in California, United States, and operates in the biotechnology sector. A portfolio of five therapeutic programs based on small molecules is maintained, targeting endocrine and metabolic disorders. The lead candidate, VK0612, is an oral drug for type 2 diabetes, while VK5211 serves as a non-steroidal selective androgen receptor modulator for cancer cachexia. Three preclinical programs address metabolic diseases and anemia.

  • Headquarters California, United States
  • Employees 36
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website vikingtherapeutics.com
  • Social LinkedIn X
  • Legal Name Viking Therapeutics, Inc.
Key Metrics
  • Net Profit
    -$359.64 M (USD)
    -227.05
    as on Dec 31, 2025
  • EBITDA
    -$392.91 M (USD)
    -160.94
    as on Dec 31, 2025
  • Total Equity Funding
    $2.5M (USD)

    in 1 rounds

  • Latest Funding Round
    $2.5M (USD), Seed

    May 2014

  • Investors
  • Employee Count
    36

Products & Services of Viking Therapeutics

Viking Therapeutics offers a comprehensive portfolio of products and services, including VK2735, VK2809, VK0214, and VK5211.

VK2735
Drug Candidate

Therapeutic for obesity and metabolic disorders via oral administration.

VK2809
Drug Candidate

Treatment for NASH and related metabolic conditions.

VK0214
Drug Candidate

Therapy for rare disease X-ALD.

VK5211
Drug Candidate

addresses hip fracture and muscle wasting.

Funding Insights of Viking Therapeutics

Viking Therapeutics has successfully raised a total of $2.5M through 1 strategic funding round. The most recent funding activity was a Seed round of $2.5 million completed in May 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $2.5M
  • Total Rounds 1
  • Last Round Seed β€” $2.5M
  • First Round $2.5M

    (May 2014)

  • Investors Count 1

All 1 funding rounds of Viking Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2014$2.5MSeed––
Valuation history

1 investors in total: 1 institutional.

Investors in Viking Therapeutics

Viking Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ligand Pharmaceuticals.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Pharmaceutical drugs are manufactured and developed in the United States.
1987ligand.comSan Diego, United States
Premium access

Investor details for Viking Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Viking Therapeutics

25 people are tracked at Viking Therapeutics (18 in leadership, 7 in team); the tracked headcount is 36.

NameRoleGroup
Brian Lian
CEOLeadership
Geoffrey Barker
VP, Pharmaceutical DevelopmentLeadership
Marianne Mancini
Chief Operating OfficerLeadership
Nils Olsson
Senior Vice President, Technical OperationsLeadership
Tavette Neskorik
Sr Director, Clinical OperationsLeadership
Carol Hall
Human Resources DirectorLeadership
Michael Morneau
VP Finance & AdministrationLeadership
Scott Stubbe
Vice President Clinical OperationsLeadership
Stephanie Herman
Associate DirectorLeadership
Sean Weigle
Director Of Finance And ControllerLeadership
Mike Morneau
Vice President, Finance And AdministrationLeadership
Shengxia Ji (Summer)
Director, Statistical Programming And Data ManagementLeadership
Greg Zante
VP Finance & OperationsLeadership
Medardo Chavez
Executive Director Business DevelopmentLeadership
Brahmachary Enugurthi
Executive Director, Pharmaceutical DevelopmentLeadership
Maureen McGonegal Barnes
Executive Director, Pharmaceutical DevelopmentLeadership
Rebecca Steele
Director, Clinical OperationsLeadership
Karen Chung
VP Health Economics & Market AccessLeadership
Rachel Frankenberger
Senior Accounting ManagerTeam
Marietta Aquino
Accounts Payable LeadTeam

5 more people are available in the full profile.

Premium access

Complete people profiles for Viking Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Viking Therapeutics

Viking Therapeutics is a publicly listed company on the NASDAQ with ticker symbol VKTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date29 Apr 2015
  • Listed onNASDAQ: VKTX
  • Listed entityViking Therapeutics, Inc.
  • Exchange sectorHealth technology
  • ISINUS92686J1060
  • Share price$26.65 (-5.96% on the day) · 2026-10-13
  • Market capitalisation$3.39B
  • EPS (diluted, trailing year)$-4.66
  • Volume (last session)5,739,223

Financials of Viking Therapeutics

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025-$359.6M-$392.9M
2024-$110.0M-$150.6M
2023-$85.9M-$100.5M
2022-$68.9M-$70.1M
2021-$55.0M-$55.4M
Premium access

Detailed financial statements for Viking Therapeutics

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Viking Therapeutics

3 dated milestones of Viking Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.

  1. Founded Viking Therapeutics is founded.
  2. Funding First funding round of $2.5M.
  3. IPO Lists on the stock exchange (IPO).

Competitors of Viking Therapeutics

Viking Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Neurocrine, Crinetics and Carmot.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
neurocrine.com1992San Diego, United States$10M1,400
Developer of small molecule therapeutics for endocrine and CNS disorders
crinetics.com2008San Diego, United States$103.5M120
Developer of therapies for the treatment of endocrine-related diseases and cancers
carmot.us2008Berkeley, United States$385.52M
Disease-modifying therapies for metabolic diseases are developed.
Premium access

Detailed competitors of Viking Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Viking Therapeutics

The website of Viking Therapeutics (vikingtherapeutics.com) receives about 31.1K visits a month and ranks #1,156,534 among all websites worldwide, #1,447 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    31.1K

    ▲ 34.2% vs previous month

  • Unique visitors
    10.3K

    per month

  • Global rank
    #1,156,534

    among all websites

  • Category rank
    #1,447

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Viking Therapeutics. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
clinicaltrialsarena.com
100%
#257,942View details
fiercebiotech.com
88%
858.3K#81,022View details
drugs.com
drugs.com
72%
#3,085–
lilly.com
67%
4.9M#13,252View details
firstwordpharma.com
firstwordpharma.com
60%
#237,108–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 6 similar websites and full traffic analytics for Viking Therapeutics

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 6 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Metabolic Diseases

3 companies that operate in the same segment as Viking Therapeutics (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Satiety induction through digestable gastric balloon introduced via a swallowed capsule
2009Wellesley, Massachusetts, United StatesUSD 174.04 MUSD 32.11 M137
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
2010Boston, Massachusetts, United StatesUSD 84 MUSD 189.76 M283
Developer of small-molecule drugs
1991Los Angeles, California, United StatesUSD 50 MUSD 348.97 M407
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Viking Therapeutics

Premium access

Complete news archive for Viking Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Viking Therapeutics

Viking Therapeutics was founded in 2012 and raised its 1st funding round 2 years after it was founded.

Viking Therapeutics is headquartered in United States. It is registered at California, United States.

Brian Lian is the CEO of Viking Therapeutics, as recorded in our data.

Viking Therapeutics is a funded company, having raised a total of $2.5M across 1 funding round to date. The company's 1st funding round was a Seed of $2.5M, raised on May 2014.

Viking Therapeutics has 36 employees.

Viking Therapeutics was founded in 2012 in California, United States, and operates in the biotechnology sector. A portfolio of five therapeutic programs based on small molecules is maintained, targeting endocrine and metabolic disorders. The lead candidate, VK0612, is an oral drug for type 2 diabetes, while VK5211 serves as a non-steroidal selective androgen receptor modulator for cancer cachexia. Three preclinical programs address metabolic diseases and anemia.

Viking Therapeutics's top competitors include Crinetics, Neurocrine and Carmot.

Viking Therapeutics offers VK2735, VK2809, VK0214, and VK5211.

Yes, Viking Therapeutics is publicly traded on NASDAQ under the ticker symbol VKTX.

Viking Therapeutics has 1 investor. Key investors include Ligand Pharmaceuticals.

Viking Therapeutics operates through Viking Therapeutics, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available